research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
Search
for
Sort by
Research
240-270 / 1000+ results 
research A spermidine-based nutritional supplement prolongs the anagen phase of hair follicles in humans: a randomized, placebo-controlled, double-blind study
A spermidine-based supplement may help hair grow longer by keeping it in the growth phase.
research First reboxetine trial results reported
Finasteride increased hair count and regrowth in men with hair loss but also caused more sexual side effects than placebo.
research Enhancing dermatology clinical trials: optimizing sites and strategies for success in India
India is ideal for dermatology trials due to diverse patients and cost-effectiveness.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
PrEP for HIV is less effective in transgender women mainly due to low adherence to the treatment.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research Investigation of topical application of procyanidin B-2 from apple to identify its potential use as a hair growing agent
Apple-derived procyanidin B-2 can safely promote hair growth in men.
research A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty
Triptorelin effectively treats central precocious puberty in Chinese children with minimal side effects.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Randomized control trial to study the efficacy and safety of platelet-rich plasma as intraoperative holding solution in hair restoration surgery: A pilot study
Using platelet-rich plasma in hair restoration surgery significantly improves hair density after 6 months and is safe to use.
research AUSTRALIAN TRIAL OF TOPICAL MINOXIDIL AND PLACEBO IN EARLY MALE PATTERN BALDNESS
Minoxidil modestly increases hair growth in men with early baldness and is safe to use.
research Low‐Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men With Androgenetic Alopecia and Boosts Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity
Light therapy reduces scalp inflammation, boosts hair regrowth with Minoxidil 2%.
research Type 2 Diabetes, Metabolic Syndrome and Lipid Metabolism
Type 2 diabetes in youth is increasing, with high treatment failure rates and more severe than Type 1; certain drugs can lower lipid levels effectively with varying side effects, and apples may benefit heart health like statins but with fewer side effects.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research DEVELOPING AND VALIDATING AN HPLC METHOD TO QUANTIFY SIMULTANEOUSLY DUTASTERIDE AND THEIR RELATED MOLECULES (DUTASTERIDE ACID, 2,5 BIS- (TRI FLUORO METHYL)-ANILINE AND DUTASTERIDE 17 α-EPIMER) IN CAPSULES
A reliable method was created to measure dutasteride and related molecules in capsules.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Registrars and Fellows Update Session 2
The session covered updates on skin treatments, including radiotherapy, imiquimod, acitretin, JAK inhibitors, and strategies for managing rosacea and preventing surgical infections.
research 943 Temporal-spatial activation of Wnt-signaling within Type1 / Type 2 immunity during wound healing
Wnt-signaling is regulated differently in skin cells and immune responses during wound healing.
research A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
Clascoterone is safe for the heart, even at high doses.
research Procyanidin B-2 and the hair-growing activity of proanthocyanidins
Procyanidin B-2 from apple juice significantly increases hair growth and may be more effective than minoxidil without side effects.
research The role of mimicking growth factors to control anagen phase: Evaluation in vitro and in vivo
Mimicking growth factors in a topical solution can prolong hair growth phase and reduce hair loss without side effects.
research Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
research Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract
Blocking enzymes that help the virus enter cells could be a promising way to treat COVID-19.
research Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study
Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
research The BJUI's clinical trials initiative
The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.
research Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.
research Innovative sequence of docetaxel–gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study
The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
research The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models
AS101 reduces hair loss from chemotherapy.